Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable saline Clear all
Completed Phase 2 Interventional Results available

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

NCT02070302
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Benjamin Sucher
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 22, 2026, 5:39 AM EDT
Terminated Phase 2 Interventional Results available

Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

NCT05378113
View directory record Official record
Conditions
Injection Site Irritation
Interventions
Ondansetron, Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Results available

Trigger Point Injections in Anterior Cervical Surgery

NCT04640896
View directory record Official record
Conditions
Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
Interventions
Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908
View directory record Official record
Conditions
Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions
Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo
Radiation · Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache

NCT00203294
View directory record Official record
Conditions
Migraine
Interventions
lidocaine, bupivicaine and saline, lidocaine plus bupivicaine plus triamcinolone (steroid)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

NCT01366820
View directory record Official record
Conditions
Brain Injuries
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
16 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Colton, California • Sacramento, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Retapamulin Microdialysis Feasibility Study

NCT01812382
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Microdialysis
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption

NCT04102761
View directory record Official record
Conditions
Internal Disc Disruption
Interventions
Intradiscal PRP & BMC Injections
Procedure
Lead sponsor
Annu Navani
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Campbell, California • Los Angeles, California • Tyler, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 22, 2026, 5:39 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

NCT04547179
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab-Vfrm, BLAfit®, Saline
Drug · Device · Other
Lead sponsor
Manhattan Beach Orthodontics
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 3 Interventional

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

NCT00518895
View directory record Official record
Conditions
Melanoma
Interventions
dacarbazine plus Genasense, dacarbazine plus placebo
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

NCT00564681
View directory record Official record
Conditions
Cervical Dystonia
Interventions
botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 22, 2026, 5:39 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

NCT07140939
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • West Palm Beach, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Not listed Not applicable Interventional

Novel Endoluminal Clinical TreAtment of Reflux

NCT03090607
View directory record Official record
Conditions
GERD
Interventions
Aluvra™, Saline
Device · Drug
Lead sponsor
Impleo Medical Inc.
Industry
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 22, 2026, 5:39 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

NCT02807181
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Results available

Pecto-Intercostal Fascial Plane Block Study

NCT04928339
View directory record Official record
Conditions
Cardiac Surgery, Opioid Use, Unspecified
Interventions
Bupivacaine Injection, Liposomal bupivacaine, Saline
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 22, 2026, 5:39 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Not applicable Interventional

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

NCT05765266
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
ACP Max™, Depo-Medrol®
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Knoxville, Tennessee • Danville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness

NCT01129583
View directory record Official record
Conditions
Post Traumatic Stiffness
Interventions
Botulinum Toxin Type A, Saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 22, 2026, 5:39 AM EDT
Withdrawn Phase 2 Interventional

Stromal Vascular Fraction (SVF) Cells for Non-Operative Treatment of Small Rotator Cuff Tears

NCT05264922
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Tisseel Injectable Product, Stromal Vascular Fraction Cells
Drug · Biological
Lead sponsor
AdventHealth
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 22, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

NCT05157841
View directory record Official record
Conditions
Bunionectomy, Hallux Valgus
Interventions
Bupivacaine liposome injectable suspension 266 mg, Bupivacaine HCl, Bupivacaine liposome injectable suspension 133 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
North Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 22, 2026, 5:39 AM EDT
Completed No phase listed Observational

Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study

NCT04804137
View directory record Official record
Conditions
Non-squamous Lung Cancer, Metastatic Lung Cancer
Interventions
Blood, sputum, saliva, stool
Other
Lead sponsor
University Hospital, Tours
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 22, 2026, 5:39 AM EDT